Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Marion Ortner, Marion Stange, Heike Schneider, Charlotte Schröder, Katharina Buerger, Claudia Müller, Felix Müller-Sarnowski, Janine Diehl-Schmid, Hans Förstl, Timo Grimmer & Werner Steimer. (2020) Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6 Genotype-Dependent Metabolism of Donepezil. Drug Design, Development and Therapy 14, pages 3251-3262.
Read now
Read now
Dana Mohammad, Parco Chan, Janelle Bradley, Krista Lanctôt & Nathan Herrmann. (2017) Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation. Expert Opinion on Drug Safety 16:9, pages 1009-1019.
Read now
Read now
Nagaendran Kandiah, Ming-Chyi Pai, Vorapun Senanarong, Irene Looi, Encarnita Ampil, Kyung Won Park, Ananda Krishna Karanam & Stephen Christopher. (2017) Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia. Clinical Interventions in Aging 12, pages 697-707.
Read now
Read now
Takemi Kimura & Junichi Takamatsu. (2013) Two cases of Alzheimer’s disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil. Neuropsychiatric Disease and Treatment 9, pages 49-53.
Read now
Read now
Michael Shanks, Miia Kivipelto, Roger Bullock & Roger Lane. (2009) Cholinesterase inhibition: is there evidence for disease-modifying effects?. Current Medical Research and Opinion 25:10, pages 2439-2446.
Read now
Read now
Norifumi Tsuno. (2009) Donepezil in the treatment of patients with Alzheimer’s disease. Expert Review of Neurotherapeutics 9:5, pages 591-598.
Read now
Read now
Richard A Hansen, Gerald Gartlehner, Aaron P Webb, Laura C Morgan, Charity G Moore & Daniel E Jonas. (2008) Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis. Clinical Interventions in Aging 3:2, pages 211-225.
Read now
Read now
Ramón Cacabelos. (2007) Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics. Neuropsychiatric Disease and Treatment 3:3, pages 303-333.
Read now
Read now
Articles from other publishers (37)
Jill S. Chotiyanonta, Kengo Onda, Milap A. Nowrangi, Xin Li, Xin Xu, Roy Adams, Constantine G. Lyketsos, Peter Zandi & Kenichi Oishi. (2023) Translating clinical notes into quantitative measures—a real-world observation on the response to cholinesterase inhibitors or selective serotonin reuptake inhibitors prescribed to outpatients with dementia using electronic medical records. Frontiers in Pharmacology 14.
Crossref
Crossref
Ezio Giacobini, A Claudio Cuello & Abraham Fisher. (2022) Reimagining cholinergic therapy for Alzheimer’s disease. Brain 145:7, pages 2250-2275.
Crossref
Crossref
Natalie Argueta, Emily Notari & Kinga Szigeti. (2022) Role of Pharmacogenomics in Individualizing Treatment for Alzheimer’s Disease. CNS Drugs 36:4, pages 365-376.
Crossref
Crossref
Chantal Vidal & Li Zhang. (2021) An Analysis of the Neurological and Molecular Alterations Underlying the Pathogenesis of Alzheimer’s Disease. Cells 10:3, pages 546.
Crossref
Crossref
Khaled S. Abd-Elrahman, Alison Hamilton, Awatif Albaker & Stephen S. G. Ferguson. (2020) mGluR5 Contribution to Neuropathology in Alzheimer Mice Is Disease Stage-Dependent. ACS Pharmacology & Translational Science 3:2, pages 334-344.
Crossref
Crossref
Patrizia Mecocci, Lucia Paolacci & Virginia Boccardi. 2020. Diagnosis and Management in Dementia. Diagnosis and Management in Dementia
457
475
.
Norifumi Tsuno, Takahiro Mori, Ichiro Ishikawa, Nobuyasu Bando, Haeyoung Park, Yoshito Matsumoto, Itsuko Mori, Mariko Tanaka, Takayuki Hirano & Yu Nakamura. (2019) Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study. Geriatrics & Gerontology International 19:7, pages 571-576.
Crossref
Crossref
Daniela Volpato & Ulrike Holzgrabe. (2018) Designing Hybrids Targeting the Cholinergic System by Modulating the Muscarinic and Nicotinic Receptors: A Concept to Treat Alzheimer’s Disease. Molecules 23:12, pages 3230.
Crossref
Crossref
Jacqueline S Birks & Richard J Harvey. (2018) Donepezil for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews 2018:6.
Crossref
Crossref
Atsushi Kuroda, Manabu Setoguchi, Yasushi Uchino, Kazuya Nagata & Daisuke Hokonohara. (2018) Effect of rivastigmine on plasma butyrylcholine esterase activity and plasma ghrelin levels in patients with dementia in Alzheimer’s disease. Geriatrics & Gerontology International 18:6, pages 886-891.
Crossref
Crossref
Shigeki Hirano, Hitoshi Shinotoh, Hitoshi Shimada, Tsuneyoshi Ota, Koichi Sato, Noriko Tanaka, Ming-Rong Zhang, Makoto Higuchi, Kiyoshi Fukushi, Toshiaki Irie, Satoshi Kuwabara & Tetsuya Suhara. (2018) Voxel-Based Acetylcholinesterase PET Study in Early and Late Onset Alzheimer’s Disease. Journal of Alzheimer's Disease 62:4, pages 1539-1548.
Crossref
Crossref
Seong Yoon Kim. (2018) Past and Future of Drug Treatments for Alzheimer's Disease. Journal of Korean Neuropsychiatric Association 57:1, pages 30.
Crossref
Crossref
Lucy Webster, Derek Groskreutz, Anna Grinbergs-Saull, Rob Howard, John T O’Brien, Gail Mountain, Sube Banerjee, Bob Woods, Robert Perneczky, Louise Lafortune, Charlotte Roberts, Jenny McCleery, James Pickett, Frances Bunn, David Challis, Georgina Charlesworth, Katie Featherstone, Chris Fox, Claire Goodman, Roy Jones, Sallie Lamb, Esme Moniz-Cook, Justine Schneider, Sasha Shepperd, Claire Surr, Jo Thompson-Coon, Clive Ballard, Carol Brayne, Orlaith Burke, Alistair Burns, Linda Clare, Peter Garrard, Patrick Kehoe, Peter Passmore, Clive Holmes, Ian Maidment, Fliss Murtagh, Louise Robinson & Gill Livingston. (2017) Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. Health Technology Assessment 21:26, pages 1-192.
Crossref
Crossref
Virginia Boccardi, Marta Baroni, Nicoletta Smirne, Alessandra Clodomiro, Sara Ercolani, Annalisa Longo, Carmelinda Ruggiero, Amalia C. Bruni & Patrizia Mecocci. (2017) Short-Term Response is not Predictive of Long-Term Response to Acetylcholinesterase Inhibitors in Old Age Subjects with Alzheimer’s Disease: A “Real World” Study. Journal of Alzheimer's Disease 56:1, pages 239-248.
Crossref
Crossref
Louis De Beaumont, Sandra Pelleieux, Louise Lamarre-Théroux, Doris Dea & Judes Poirier. (2016) Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer’s Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects. Journal of Alzheimer's Disease 54:3, pages 913-922.
Crossref
Crossref
Hiroaki Kazui, Kenji Yoshiyama, Hideki Kanemoto, Yukiko Suzuki, Shunsuke Sato, Mamoru Hashimoto, Manabu Ikeda, Hibiki Tanaka, Yutaka Hatada, Masateru Matsushita, Yoshiyuki Nishio, Etsuro Mori, Satoshi Tanimukai, Kenjiro Komori, Taku Yoshida, Hideaki Shimizu, Teruhisa Matsumoto, Takaaki Mori, Tetsuo Kashibayashi, Kazumasa Yokoyama, Tatsuo Shimomura, Yasunobu Kabeshita, Hiroyoshi Adachi & Toshihisa Tanaka. (2016) Differences of Behavioral and Psychological Symptoms of Dementia in Disease Severity in Four Major Dementias. PLOS ONE 11:8, pages e0161092.
Crossref
Crossref
Jacqueline S Birks, Lee-Yee Chong & John Grimley Evans. (2015) Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Alireza Atri & Theodore A. Stern. (2015) Psychopharmacologic Agents to Enhance Cognition in Alzheimer’s Disease. Psychiatric Annals 45:7.
Crossref
Crossref
Jacqueline S Birks & John Grimley Evans. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
G.F. Bono, D.P. Sim?o-Silva, M.S. Batistela, N.D. Josviak, P.F.R. Dias, G.A. Nascimento, R.L.R. Souza, M.R. Piovezan, R.K.M. Souza & L. Furtado-Alle. (2015) Butyrylcholinesterase: K variant, plasma activity, molecular forms and rivastigmine treatment in Alzheimer's disease in a Southern Brazilian population. Neurochemistry International 81, pages 57-62.
Crossref
Crossref
Shuichi Yanai & Shogo Endo. 2015. Aging Mechanisms. Aging Mechanisms
257
274
.
David Riascos, Alexander Nicholas, Ravand Samaeekia, Rustam Yukhananov, M.-Marsel Mesulam, Eileen H. Bigio, Sandra Weintraub, Ling Guo & Changiz Geula. (2014) Alterations of Ca2+-responsive proteins within cholinergic neurons in aging and Alzheimer's disease. Neurobiology of Aging 35:6, pages 1325-1333.
Crossref
Crossref
Karen Levy, Krista L. Lanctôt, Shale B. Farber, Abby Li & Nathan Herrmann. (2012) Does Pharmacological Treatment of Neuropsychiatric Symptoms in Alzheimerʼs Disease Relieve Caregiver Burden?. Drugs & Aging 29:3, pages 167-179.
Crossref
Crossref
C E Patterson, S A Todd & A P Passmore. (2010) Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease. The Pharmacogenomics Journal 11:6, pages 444-450.
Crossref
Crossref
David Riascos, Dianne de Leon, Alaina Baker-Nigh, Alexander Nicholas, Rustam Yukhananov, Jing Bu, Chuang-Kuo Wu & Changiz Geula. (2011) Age-related loss of calcium buffering and selective neuronal vulnerability in Alzheimer?s disease. Acta Neuropathologica 122:5, pages 565-576.
Crossref
Crossref
Caterina Chianella, Daniela Gragnaniello, Pierpaolo Maisano Delser, Maria Francesca Visentini, Elisabetta Sette, Maria Rosaria Tola, Guido Barbujani & Silvia Fuselli. (2011) BCHE and CYP2D6 genetic variation in Alzheimer’s disease patients treated with cholinesterase inhibitors. European Journal of Clinical Pharmacology 67:11, pages 1147-1157.
Crossref
Crossref
N. N. Nalivaeva, N. Z. Makova, E. G. Kochkina, D. John, V. A. Arutyunov, L. S. Kozina, A. V. Arutjunyan & I. A. Zhuravin. (2011) Effects of geroprotective peptides on the activity of cholinesterases and formation of the soluble form of the amyloid precursor protein in human neuroblastoma SH-SY5Y cells. Neurochemical Journal 5:3, pages 176-182.
Crossref
Crossref
Florinda Ferreri, Patrizio Pasqualetti, Sara Määttä, David Ponzo, Andrea Guerra, Federica Bressi, Paola Chiovenda, Marco del Duca, Federica Giambattistelli, Francesca Ursini, Mario Tombini, Fabrizio Vernieri & Paolo Maria Rossini. (2011) Motor cortex excitability in Alzheimer's disease: a transcranial magnetic stimulation follow-up study. Neuroscience Letters 492:2, pages 94-98.
Crossref
Crossref
Alberto PilottoM. FranceschiG. D’OnofrioA. BizzarroF. MangialascheL. CascavillaF. ParisM. G. MateraAndrea PilottoA. DanieleP. MecocciC. MasulloB. DallapiccolaD. Seripa. (2009)
Effect of a
CYP2D6
polymorphism on the efficacy of donepezil in patients with Alzheimer disease
. Neurology 73:10, pages 761-767.
Crossref
Crossref
Jacqueline Birks, John Grimley Evans, Vasso Iakovidou & Magda Tsolaki. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Ramón Cacabelos. 2008. Pharmacogenomics and Personalized Medicine. Pharmacogenomics and Personalized Medicine
317
368
.
Ramón Cacabelos. 2008. Pharmacogenomics in Drug Discovery and Development. Pharmacogenomics in Drug Discovery and Development
213
357
.
Howard H Feldman, Steven Ferris, Bengt Winblad, Nikolaos Sfikas, Linda Mancione, Yunsheng He, Sibel Tekin, Alistair Burns, Jeffrey Cummings, Teodoro del Ser, Domenico Inzitari, Jean-Marc Orgogozo, Heinrich Sauer, Philip Scheltens, Elio Scarpini, Nathan Herrmann, Martin Farlow, Steven Potkin, H Cecil Charles, Nick C Fox & Roger Lane. (2007) Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. The Lancet Neurology 6:6, pages 501-512.
Crossref
Crossref
Karen Ritchie & Florence Portet. (2006) ‘I think therefore I am’: improving cognition. Current Opinion in Psychiatry 19:6, pages 570-574.
Crossref
Crossref
Rafael Blesa, Roger Bullock, Yunsheng He, Howard Bergman, Giuseppe Gambina, Joanne Meyer, Günter Rapatz, Jennifer Nagel & Roger Lane. (2006) Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenetics and Genomics 16:11, pages 771-774.
Crossref
Crossref
. (2006) Current awareness in geriatric psychiatry. International Journal of Geriatric Psychiatry 21:11, pages 1107-1114.
Crossref
Crossref
Serge Gauthier, Bruno Vellas, Martin Farlow & David Burn. (2006) Aggressive course of disease in dementia. Alzheimer's & Dementia 2:3, pages 210-217.
Crossref
Crossref